Lupin spins out two phase-1 cancer candidates into US startup Kaveri, taking majority stake and providing seed funding
Lupin, an Indian generics manufacturer, has created a U.S.-based spinout called Kaveri Therapeutics by transferring two clinical-phase cancer drug candidates.
The assets are a PRMT5 inhibitor (LNP7457) and a SOS1 inhibitor (LNP8701). Phase-1 studies reported preliminary efficacy signals and tolerability in patients with metastatic solid tumors.
Lupin retains an 82.2% ownership in Kaveri, valued at about $1.6 million, and will provide seed funding while the new company seeks additional capital for further development.
Kaveri has appointed Kristi Jones as CEO and Robert Pierce as chief medical officer to lead the independent entity.
This writeup was produced by pharmadog from original reporting by Fierce Biotech.
Original headline: “Indian generics maker Lupin seeds US spinout Kaveri with cash, clinical-phase cancer assets”
read at Fierce Biotech ↗
comments(0)
5-min edit window · permanent after that